A phase 1, randomized, double-blind, placebo controlled, multi-dose study to determine the safety, tolerance and pharmacokinetics of 3 dose levels of AT-1001 [larazotide] in healthy volunteers

Trial Profile

A phase 1, randomized, double-blind, placebo controlled, multi-dose study to determine the safety, tolerance and pharmacokinetics of 3 dose levels of AT-1001 [larazotide] in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2006

At a glance

  • Drugs Larazotide (Primary)
  • Indications Coeliac disease; Crohn's disease; Irritable bowel syndrome; Type 1 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Alba Therapeutics
  • Most Recent Events

    • 17 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top